Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Leukemia
Interventions: lintuzumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Orthopaedic Trauma, Chronic Opioid Use
Interventions: Ketorolac Injection, Standard of Care (SOC) Multimodal Analgesia; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Healthy
Interventions: FosD, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hematopoietic Stem Cells
Interventions: Vedolizumab Placebo, Vedolizumab; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more

Conditions: Cataract
Interventions: TriMoxiVanc, Moxifloxacin HCl 0.5%, Ilevro, Prednisolone acetate 1%; Drug
Lead sponsor: Carolina Eyecare Physicians, LLC; Other
Eligibility: 50 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Bloomington, Minnesota • Stillwater, Minnesota • Garden City, New York + 1 more

Conditions: Healthy Adults
Interventions: EC5026 oral capsule, Placebo oral capsule; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
Interventions: Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet; Drug · Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Focus: Hospitalized Patients
Interventions: Nurse Home Visit, Standard of Care; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 18 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Wrinkles
Interventions: Botulinum Toxin, Chemical Peel Only; Drug · Procedure
Lead sponsor: Loyola University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: La Grange Park, Illinois

Conditions: Hilar Cholangiocarcinoma
Interventions: Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen; Drug · Procedure
Lead sponsor: Concordia Laboratories Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 18
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more

Conditions: Ankylosing Spondylitis
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Irvine, California • La Mesa, California • San Leandro, California + 22 more

Conditions: HPV Infection
Interventions: Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypochondroplasia
Interventions: Vosoritide, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 0 Months to 36 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more

Conditions: Bowel Preparation, Efficacy, Tolerability, Safety, Colon Cancer Screening, Bowel Preparation for Colonoscopy
Interventions: Use of a standardized meal content (food-kit) the day prior to colonoscopy, Polyethylene glycol 3350 - electrolyte solution (GoLYTELY); Other · Drug
Lead sponsor: Joseph Spataro; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Other Abortion, Spontaneous Abortion
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 3
States / cities: San Diego, California • Aurora, Colorado • Indianapolis, Indiana

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Pharmacokinetics
Interventions: TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Contact Lens Wear
Interventions: Complete MPS, NNR06; Device
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Pittsburg, Kansas

Conditions: Cachexia
Interventions: VT-122 low dose, VT-122 high dose; Drug
Lead sponsor: Vicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more

Conditions: Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions: VP-102 and applicator, Placebo; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more

Search by objective public record fields.

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Dropless vs. Standard Drops Contralateral Eye Study

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

Phentermine/Topiramate for Uric Acid Stones

Hospital to Home Outcomes

Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives

Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

Regimen for the Treatment of Cachexia in Subjects With NSCLC

Intensive Models of HCV Care for Injection Drug Users

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts